Estadístiques de Palbociclib with fulvestrant or letrozole in endocrine-sensitive patients with HR-Positive/HER2-Negative advanced breast cancer: A detailed safety analysis of the randomized PARSIFAL trial
Visites totals
| views | |
|---|---|
| Palbociclib with fulvestrant or letrozole in endocrine-sensitive patients with HR-Positive/HER2-Negative advanced breast cancer: A detailed safety analysis of the randomized PARSIFAL trial | 36 |
Visites totals per mes
| views | |
|---|---|
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 1 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| Cosimo_onc_palb.pdf | 33 |
| Cosimo_onc_palb.pdf(legacy) | 21 |
Vistes principals per país
| views | |
|---|---|
| United States | 28 |
| Spain | 4 |
| Australia | 1 |
| Belgium | 1 |
| India | 1 |
| Malaysia | 1 |
Visites principals per ciutat
| views | |
|---|---|
| Ann Arbor | 5 |
| Boardman | 5 |
| San Ramon | 5 |
| Barcelona | 4 |
| Fairfield | 4 |
| Menlo Park | 3 |
| Mountain View | 2 |
| Cupertino | 1 |
| Mira Road | 1 |
| Petaling Jaya | 1 |
| Pinjarra | 1 |
| San Diego | 1 |